Kyowa Kirin Teams With AstraZeneca For Cancer Immunotherapies
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin and AstraZeneca have entered into an agreement regarding cancer immunotherapy development, focusing on combination products.